IDYA – ideaya biosciences, inc. (US:NASDAQ)
Stock Stats
News
4/26
06:00 am
idya
Medium
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/24
10:11 am
idya
Low
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study [Yahoo! Finance]
4/24
10:05 am
idya
Low
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
4/22
06:08 am
idya
Low
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer [Yahoo! Finance]
4/22
06:00 am
idya
Low
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
5/9/2023
06:00 am
idya
17.2%
BEAT
3/21
12:14 pm
Maintains
Buy
Buy
Citigroup
Low
0.2%
3/21
12:14 pm
Maintains
Buy
Buy
Citigroup
Low
0.2%
3/8
09:13 am
Initiates
Buy
BTIG
Low
0.7%
3/8
08:23 am
Initiates
Buy
BTIG Research
Low
0.5%
2/23
12:21 pm
Maintains
Overweight
Overweight
JP Morgan
Low
-0.6%
4/24
04:01 pm
idya
Medium
Form ARS IDEAYA Biosciences, Inc. For: Dec 31
4/19
09:01 am
idya
Medium
Form DEF 14A IDEAYA Biosciences, Inc. For: May 31
3/12
06:04 am
idya
Low
Form 8-K IDEAYA Biosciences, Inc. For: Mar 08
3/4
05:29 pm
idya
Medium
Form 4 IDEAYA Biosciences, Inc. For: Mar 01 Filed by: Hata Yujiro S
3/4
05:28 pm
idya
Medium
Form 4 IDEAYA Biosciences, Inc. For: Mar 01 Filed by: Ruiz Briseno Andres
Show more
Top News Gainers
11/13 Q3/2019 9/30/2019 EPS -0.540 ZacksConsensus -0.670 ActVsEst 0.130 - Beat 47.4%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
Top News Decliners
11/20 Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress -23.8%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3